Abstract
Epidermal growth factor receptor (EGFR)-mutated (exons 18–21) advanced non-small cell lung cancers (NSCLCs) are generally characterized by exquisite sensitivity to treatment with an EGFR-tyrosine kinase inhibitor (-TKI). First-generation or reversible EGFR-TKIs include gefitinib and erlotinib, while, more recently, second-generation or irreversible EGFR-TKIs have been developed, namely afatinib and dacomitinib, with the aim of overcoming/delaying acquired resistance to treatment. Nevertheless, clinical trials have shown that resistance eventually emerges after a median time of slightly less than one year, regardless of whether first- or second-generation EGFR-TKIs are used. In this context, a secondary EGFR mutation in exon 20, namely T790M, has been found to be responsible for approximately 60% of cases of acquired resistance. Alternatively, T790M resistance mutation can be found de novo, in which case it limits the antitumor activity of both first- or second-generation EGFR-TKIs. Osimertinb is an orally bioavailable, third-generation EGFR-TKI that acts by irreversibly binding both EGFR activating mutations and T790M, while sparing wild-type EGFR. On this basis, osimertinib has proven more efficacious than platinum-based chemotherapy in the setting of EGFR T790M-positive NSCLCs pretreated with a first- or second-generation EGFR-TKI. More recently, in another phase 3 trial, osimertinib outperformed gefitinib or erlotinib as first-line treatment of EGFR-mutated (ex19del or L858R) advanced NSCLCs, thus emerging as a new standard of care in this setting. In the present review, we will discuss the preclinical and clinical development of osimertinib, briefly touching upon its activity in special populations and biomarkers of sensitivity to treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ahn MJ, Yang J, Yu H et al (2016) 1360: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J Thorac Oncol 11(4suppl):S115
Ballard P, Yates JW, Yang Z et al (2016) Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 22:5130–5140
Bersanelli M, Minari R, Bordi P et al (2016) L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC. J Thorac Oncol 11:e121–123
Costa DB (2016) Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements. Transl Lung Cancer Res 5:331–337
Cross DA, Ashton SE, Ghiorghiu S et al (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4:1046–1061
De Marinis F, Cho BC, Kim DW et al (2017) ASTRIS: a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC). J Clin Oncol 35(suppl; abstr 9036)
Dong L, Lei D, Zhang H (2017) Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients. Oncotarget 8:64600–64606
Goss G, Tsai CM, Shepherd FA et al (2016) Osimertinib for pretreated EGFR Thr790 Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 17:1643–1652
Goss G, Tsai CM, Shepherd FA et al (2018) CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol 29:687–693
Heon S, Yeap BY, Britt GJ et al (2010) Development of central nervous sys- tem metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 16:5873–5882
Ho CC, Liao WY, Lin CA et al (2017) Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. J Thorac Oncol 12:567–572
Jänne PA, Yang JC, Kim DW et al (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689–1699
Jamal-Hanjani M, Spicer J (2012) Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 18:938–944
Koba T, Kijima T, Takimoto T et al (2017) Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: two case reports. Medicine (Baltimore) 96:e6087
Kobayashi Y, Mitsudomi T (2016) Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci 107:1179–1186
Li L, Wang H, Li C et al (2017) Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: a case report. Oncotarget 8:18609–18614
Liang W, Wu X, Fang W et al (2014) Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS ONE 9:e85245
Losanno T, Gridelli C (2017) Recent advances in targeted advanced lung cancer therapy in the elderly. Expert Rev Anticancer Ther 17:787–797
Malapelle U, Pisapia P, Rocco D et al (2016) Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. Transl Lung Cancer Res 5:505–510
Malapelle U, de-Las-Casas MC, Rocco D et al (2017) Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. Br J Cancer 116:802–810
Metro G, Crinò L (2011) The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev Anticancer Ther 11:673–682
Metro G, Crinò L (2012) Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res 1:5–13
Metro G, Chiari R, Ricciuti B et al (2015) Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. Expert Opin Pharmacother 16:2601–2613
Mok TS, Wu Y-L, Ahn M-J et al (2017a) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629–640
Mok T, Ahn M-J, Han J-Y et al (2017b) CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: data from a randomized phase III trial (AURA3). J Clin Oncol 35 (suppl; abstr 9005)
Novello S, Barlesi F, Califano R et al (2016) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v1–v27
Oxnard GR, Thress KS, Alden RS et al (2016) Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 34:3375–3382
Pisapia P, Pepe F, Smeraglio R et al (2017) Cell free DNA analysis by SiRe(®) next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. J Thorac Dis 9(suppl 13):S1383–S1390
Planchard D, Loriot Y, André F et al (2015) EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol 26:2073–2078
Planchard D, Brown KH, Kim DW et al (2016) Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol 77:767–776
Ramalingam SS, Yang JC, Lee CK et al (2018) Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol 36:841–849
Reichegger H, Jochum W, Förbs D et al (2016) Rapid intracranial response to osimertinib in a patient with epidermal growth factor receptor T790M-positive adenocarcinoma of the lung. Oncol Res Treat 39:461–463
Ricciuti B, Chiari R, Chiarini P et al (2016) Osimertinib (AZD9291) and CNS response in two radiotherapy-naïve patients with EGFR-mutant and T790M-positive advanced non-small cell lung cancer. Clin Drug Invest 36:683–686
Santarpia M, Liguori A, Karachaliou N et al (2017) Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer (Auckl) 8:109–125
Shi YK, Wang L, Han BH et al (2017) First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol 28:2443–2450
Sonoda T, Yanagitani N, Saiki M et al (2017) The efficacy and toxicity of osimertinib in T790M-positive NSCLC with acquired resistance to EGFR-TKI in clinical practice. J Clin Oncol 35 (suppl; abstr e20575)
Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125
Tagrisso—European Medicines Agency—Europa EU. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/004124/WC500202022.pdf. Last accessed 1 Jan 2018
TAGRISSO (osimertinib) tablets, for oral use—FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208065s006lbl.pdf. Last accessed 1 Jan 2018
Tazza M, Metro G (2017) Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy. J Thorac Dis 9:4064–4069
Thress KS, Paweletz CP, Felip E et al (2015) Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21:560–562
Uemura T, Oguri T, Okayama M et al (2017) Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: a case report. Mol Clin Oncol 6:525–528
Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E et al (2018) The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small-cell lung cancer and in healthy volunteers. J Clin Pharmacol 58:474–484
Wang S, Cang S, Liu D et al (2016) Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol 9:34
Wu YL, Cheng Y, Zhou X et al (2017) Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 18:1454–1466
Yang JCH, Ramalingam SS, Janne PA et al. (2016a) Osimertinib (AZD9291) in pre-treated pts with T790 M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 11 (suppl; abstr S152–153)
Yang JCH, Kim DW, Kim SW et al (2016b) Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study. J Clin Oncol 34(suppl; abstr 9002)
Yang JC, Ahn MJ, Kim DW et al (2017a) Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol 35:1288–1296
Yang JCH, Cho BC, Kim DW et al (2017b) Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): updated results from the BLOOM study. J Clin Oncol 35(suppl; abstr 2020)
Yonesaka K, Kudo K, Nishida S et al (2015) The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget 6:33602–33611
Zhang H (2016) Osimertinib making a breakthrough in lung cancer targeted therapy. Onco Targets Ther 9:5489–5493
Zhang XY, Zhang YK, Wang YJ et al (2016) Osimertinib (AZD9291), a mutant-selective EGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Molecules 15:21
Acknowledgements
The authors report no grant funding for this work. The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Malapelle, U. et al. (2018). Osimertinib. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 211. Springer, Cham. https://doi.org/10.1007/978-3-319-91442-8_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-91442-8_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-91441-1
Online ISBN: 978-3-319-91442-8
eBook Packages: MedicineMedicine (R0)